Back

Opus Genetics receives Buy rating and $8 price target

Verifying
  • Opus Genetics received a Buy rating from analyst Matthew Caufield.
  • $8 was the price target assigned to Opus Genetics in August 2026.
  • Opus Genetics plans to release topline Phase 1/2 data for OPGx-BEST1.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.